Biotricity Beheer

Beheer criteriumcontroles 2/4

De CEO Biotricity is Waqaas Al-Siddiq, benoemd in Jul2014, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.25M, bestaande uit 38.3% salaris en 61.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.4% van de aandelen van het bedrijf, ter waarde $ 279.63K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 7.2 jaar.

Belangrijke informatie

Waqaas Al-Siddiq

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	38.3%
Dienstverband CEO	10.3yrs
Eigendom CEO	3.4%
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	7.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Waqaas Al-Siddiq's beloning veranderd ten opzichte van Biotricity's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	US$1m	US$480k	-US$15m
Dec 31 2023	n/a	n/a	-US$15m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	US$1m	US$480k	-US$20m
Dec 31 2022	n/a	n/a	-US$21m
Sep 30 2022	n/a	n/a	-US$23m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	US$887k	US$480k	-US$30m
Dec 31 2021	n/a	n/a	-US$30m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	US$891k	US$390k	-US$16m
Dec 31 2020	n/a	n/a	-US$16m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	US$2m	US$390k	-US$11m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	US$2m	US$360k	-US$9m
Dec 31 2018	n/a	n/a	-US$10m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	US$1m	US$310k	-US$9m

Compensatie versus markt: De totale vergoeding ($USD 1.25M ) Waqaas } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Waqaas is gestegen terwijl het bedrijf verliesgevend is.

CEO

Waqaas Al-Siddiq (39 yo)

10.3yrs

Tenure

US$1,254,153

Compensatie

Dr. Waqaas Al-Siddiq, PhD, has founded Biotricity Inc.(formerly known as iMedical Innovations Inc.) in July 2014 and has been its Chairman, President and Chief Executive Officer since July 2014. Dr. Al-Sid...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Waqaas Al-Siddiq	Founder	10.3yrs	US$1.25m	3.4% $ 279.6k
S. Ayanoglou	Chief Financial Officer	7.1yrs	US$562.00k	1.19% $ 97.6k
Amjad Talpur	Senior Director of Operations	no data	geen gegevens	geen gegevens
Matt Zabel	Vice President of Sales & Strategy	no data	geen gegevens	geen gegevens
Amir Ali	Chief Development Officer	no data	geen gegevens	geen gegevens
Fareeha Siddiqui	Executive Vice President of Healthcare Solutions	less than a year	geen gegevens	geen gegevens

7.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van BTCY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Waqaas Al-Siddiq	Founder	10.3yrs	US$1.25m	3.4% $ 279.6k
John Simpson	Chair of Scientific & Medical Alliance Board and Chair of Science Alliance Board	4.7yrs	geen gegevens	geen gegevens
Daniel Sands	Member of the Board of Advisors	8.5yrs	geen gegevens	geen gegevens
Ronald McClurg	Independent Director	2.5yrs	US$32.62k	0.15% $ 12.6k
David Rosa	Independent Director	8.5yrs	US$60.00k	1.3% $ 106.6k
J. Rice	Member of the Board of Advisors	8.4yrs	geen gegevens	geen gegevens
John Rother	Member of the Board of Advisors	8.5yrs	geen gegevens	geen gegevens
Thomas Nelson	Member of the Board of Advisors	8.4yrs	geen gegevens	geen gegevens
Donald Cross	Member of Scientific & Medical Alliance Board	6yrs	geen gegevens	geen gegevens
Edward Lazaga	Member of Scientific & Medical Alliance Board	6yrs	geen gegevens	geen gegevens
Imran Mohiuddin	Member of Scientific & Medical Alliance Board	6yrs	geen gegevens	geen gegevens
Radoslaw Kiesz	Member of Scientific & Medical Alliance Board	6yrs	geen gegevens	geen gegevens

7.2yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BTCY wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).

Biotricity Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Less than half of directors are independent

Less than half of directors are independent

Biotricity Announces Management Changes

High number of new directors

High number of new directors

Recent updates

Biotricity Kicks Off Another Pilot Program with A Major Hospital System That Services over 800,000 Individuals

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Biotricity, Inc. announced a financing transaction

Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023)

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity Releases Another Groundbreaking Product: Biotres Pro

New major risk - Market cap size

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device

Biotricity, Inc. has completed a Follow-on Equity Offering.

New major risk - Financial position

First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023)

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications

Biotricity Regains Nasdaq Listing Compliance

Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023

Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022)

Third quarter 2023 earnings: Revenues exceed analyst expectations

Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price

Consensus revenue estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$3.83

Less than half of directors are independent

Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

Less than half of directors are independent

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity Announces Management Changes

Biotricity, Inc.: A First Take

Biotricity, Inc. announced delayed annual 10-K filing

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022

High number of new directors

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

High number of new directors

Biotricity: Capital Raise Leads To Buying Opportunity

Biotricity Common Stock Deleted from Other OTC

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022

Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021

Biotricity, Inc. announced that it has received $9.5575 million in funding

Biotricity Announces New Solution for Personal Heart Management with Bioheart

Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres

Biotricity Inc. Announces Launch of Its Bioflux® Direct Program

Biotricity, Inc. announced a financing transaction

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam